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Pharmaco- and therapygenetic aspects in the treatment  
of anxiety disorders beyond the serotonergic system:  
a brief review
Anxiety disorders (ADs) are among the most frequent psychiatric disorders. In addition, key 
features of ADs include that they are among the earliest mental disorders to manifest and 
that their first specific treatment frequently occurs several years after the onset of symptoms. 
Although the heritability of anxiety disorders is well known, the genetic determination of 
response to different modalities (psycho- or pharmacotherapy) used in treatment of patients 
with ADs is lesser investigated. Several studies focused on the role of serotonergic genes in 
the etiopathology and pharmacotherapy of anxiety disorders, however, less attention was 
paid to variants of other genes. In this review we focus on the cytochrome P 450, BDNF, COMT, 
MAOA, EAA-3 transporter, dopamine transporter and dopamine receptor gene polymorphisms 
and their effects with respect to the pharmacogenetics of anxiety disorders. We discuss the 
current knowledge on pharmacogenetic/therapygenetic aspects of anxiety disorders beyond 
the serotonergic system.
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Epidemiological data suggest that the group of anxi-ety disorders (ADs) is the most prevalent class of 
psychiatric disorders (Kessler et al. 2010), with about 
one in five adults suffering from an anxiety disorder 
in the U.S. population (Merikangas and Kalaydjian 
2009). The range of lifetime-prevalence data of differ-
ent ADS are as follows: specific phobia 1.5-12%; social 
phobia 0.2-9.4%; OCD 0.1-3%; GAD 0.1-6.9%; panic 
disorder 0.2-5%; PTSD from 1 to over 10% (the wide 
range of prevalence data mirrors that these are derived 
from populations of different countries) (Merikangas 
and Kalaydjian 2009; Kessler et al. 2010).
In general, the onset of different ADs mainly 
occurs in childhood or adolescence (for example, 
the National Comorbidity Survey-Replication found 
that the median age at onset of ADS was 12 years) 
(Merikangas and Kalaydjian 2009; Kessler et al. 2010), 
indicating that ADs have an earlier onset compared 
to other “major” psychiatric diseases such as mood or 
substance use disorders and nonaffective psychoses 
(Merikangas and Kalaydjian 2009; Kessler et al. 2010). 
The genetic contribution to the pathogenesis of ADs 
is widely known. The heritability of different types of 
ADs varies from 30% (PTSD) to 67% (agoraphobia) 
(Domschke and Deckert in press). Linkage and as-
sociation studies identified several loci of interest and 
susceptibility genes associated with ADs (for a recent 
review see Domschke and Deckert (in press). The role 
of several neurotransmitter systems in the mediation 
of different anxious symptoms has been raised in the 
literature. Accordingly, besides the main inhibitory 
and excitatory amino acid transmitters of the central 
nervous system (GABA and glutamate, respectively) 
monoaminergic neurotransmitters (such as serotonin, 
dopamine and (nor)adrenalin), several neuropeptides 
(e.g. neuropeptide Y, neuropeptide S, cholecystokinin) 
and some other transmitters (e.g. endocannabinoids) 
are also involved in the neurochemistry of anxiety 
(Durant et al. 2010; Lazary et al. 2011; Wu et al. 2011; 
Klauke et al. in press).
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Pharmacotherapy and different types of psychother-
apy are the two widely used and effective treatment 
modalities for ADs (Ravindran and Stein 2010). The 
pharmacologic armamentarium for the treatment of 
ADs includes agents from several different classes of 
drugs. Accordingly, many classes of antidepressants 
(e.g. selective serotonin reuptake inhibitors (SSRI), 
serotonin noradrenaline reuptake inhibitors (SNRI), 
tricyclic antidepressants (TCA) and monoamine oxi-
dase inhibitors (MAOI)), as well as benzodiazepines 
(BZD), azapirones (e.g. buspirone), the anticonvulsant 
agent pregabalin and the antihistamine hydroxyzine 
are in use for the treatment of ADs (for a review 
see (Bandelow et al. 2008; Ravindran and Stein 
2010) indicating a diverse molecular background of 
antidepressants.
While a large number of pharmacogenetic stud-
ies were conducted in patients with mood disorders 
it is surprising that – despite the significant magni-
tude of social and personal burdens of ADs – only a 
relatively few studies have specifically investigated 
the genetic aspects of response to treatment among 
individuals with ADs to date (Schosser and Kasper 
2009; Domschke and Deckert in press). A PubMed 
search performed in October 2012 with the terms 
“pharmacogenetics” and “anxiety” or “anxiolytics” has 
provided only 84 and 102 results, respectively; while 
a search with the terms “pharmacogenetics” and “de-
pression” or “antidepressants” provided 322 and 480 
results, respectively.
In case of the etiopathology of anxiety disorders, 
genes of the serotonergic system are the most exten-
sively studied candidates. There are several recent 
reviews that address this question (Lesch et al. 2003; 
Maron and Shlik 2006; Lowry et al. 2008; Akimova 
et al. 2009; Lazary et al. 2011; Fernandez and Gaspar 
2012; Domschke and Deckert in press) and there 
are also various papers, although with inconsistent 
results, which focus on the role of serotonergic genes 
in the response to pharmacotherapy in various anxiety 
disorders (Perna et al. 2005; Kim et al. 2006; Schosser 
and Kasper 2009; Maron et al. 2010; Yevtushenko et 
al. 2010; Yevtushenko and Reynolds 2010; Ishiguro 
et al. 2011; Mekli et al. 2011; Andrisano et al. 2012; 
Brandl et al. 2012; Corregiari et al. 2012; Narasimhan 
and Lohoff 2012; Lohoff et al. in press a; Lohoff et al. 
in press b). Therefore in our present review we focus 
on other pharmacogenetic aspects beyond those 
related to the serotonergic system, reviewing the 
CYP 450 system that has a crucial role in pharma-
cokinetic processes, and BDNF, COMT, dopamine 
receptor, dopamine transporter (DAT) and EAAT3 
genes, which are important in the pharmacodynamic 
aspects of the treatment of anxiety disorders. 
Candidate genes in the pharmaCo-
genetiC studies in anxiety disorders
The cytochrome P450 enzyme system
The cytochrome P450s (CYPs) are members of a su-
perfamily of oxidative enzymes, and act as the major 
system for phase I oxidative metabolism of approxi-
mately 80% of the commonly used therapeutic sub-
stances (Weizman et al. 2012). Drug metabolising 
enzymes of the phase II reactions (e.g. glucuronyl 
transferases, acetyltransferases and glutathione 
S-transferases) also show genetic variability with 
functional consequences, but since the majority of 
psychotropics are extensively metabolized by enzymes 
of phase I, most of the clinically relevant metabolism-
related pharmacogenetic effects are attributable to 
phase I reactions, with some noteworthy exceptions 
like the case of lamotrigine (Stingl et al. in press).
The clinically most important isoenzymes of he-
patic CYPs, regarding benzodiazepine and antidepres-
sant metabolism, are CYP1A2, CYP2C9/19, CYP2D6 
and CYP3A4 (Tiwari et al. 2009; Weizman et al. 2012). 
Interindividual and interethnic differences within 
CYP450 genes may contribute to altered activity of 
different CYP isoenzymes. This genetic variability in 
enzyme activity may lead to differences in efficacy (i.e. 
treatment response), side-effects and intoxication 
frequency between individuals during pharmaco-
logical treatment. It is notable that not only genetic 
effects but also environmental effects (e.g. smoking, 
caffeine intake, grapefruit juice consumption) and 
intake of other medications may influence the activity 
of some isoenzymes of the CYP450 family (Paine et 
al. 2004; Tiwari et al. 2009; Dome et al. 2010; Brandl 
et al. 2012; Muller et al. 2012; Weizman et al. 2012; 
Stingl et al. in press). The degree of genetic variability 
differs between distinct members of CYP450 enzymes. 
Accordingly, degrees of polymorphism in genes for 
CYP2D6 and CYP2C19 are high, for CYP1A2 and 
CYP2C9 are medium and for CYP3A4 is low (Stingl 
et al. in press). 
In accordance with the paramounting importance 
of CYP enzymes in the metabolism of psychotropic 
medications it is not surprising that a large number 
of investigations concerning the association between 
different CYP enzyme variants and response and/or 
side effect profile to antidepressive agents were carried 
out in patients with major depression (Weizman et 
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al. 2012). However, although we know that different 
genetic variations of some CYP enzymes are associ-
ated with altered plasma levels of benzodiazepines 
and antidepressants used in the treatment of ADs, and 
also that plasma concentrations of these medications 
may be associated with treatment response in anxiety 
disorder patients, the number of investigations which 
deal with the effect of CYP polymorphisms on treat-
ment response in patients with ADs is surprisingly 
low (Lesser et al. 1992; Fukasawa et al. 2007; Tiwari 
et al. 2009; Brandl et al. 2012).
Van Nieuwerburgh et al. was not able to find a sig-
nificant effect of CYP2D6 gene variants on treatment 
response to paroxetine or venlafaxine among OCD 
patients in a 12-weeks study (although they found 
that CYP2D6 variants determined plasma levels of 
both agents) (Van Nieuwerburgh et al. 2009). On the 
contrary, in a sample of OCD patients treated with 
one or more trials of clomipramine or SSRIs Müller 
et al. found that CYP2D6 status was associated with 
therapeutic response (Muller et al. 2012).
Brain-derived neurotrophic factor (BDNF)
There are several lines of evidence that suggest that 
BDNF is involved in both the pathogenesis and treat-
ment of ADs (Chen et al. 2006; Schosser and Kasper 
2009; Soliman et al. 2010; Hong et al. 2011; Domschke 
and Deckert in press).
Rs6265 is a well-known SNP within the BDNF 
gene resulting in a valine to methionine (Val66Met) 
substitution, influencing activity-dependent BDNF 
secretion, brain morphology and memory functions. 
Furthermore, some results suggest it is also associated 
with anxiety susceptibility (notwithstanding associa-
tions of this SNP with risks of specific types of ADS 
(PD; OCD; PTSD; etc.) remained unproven), and also 
has an effect on antidepressant treatment response 
in depression (Chen et al. 2006; Soliman et al. 2010; 
Hong et al. 2011; Brandl et al. 2012; Weizman et al. 
2012). However, Narasimhan et al. was unable to find 
an effect of rs6265 on treatment response to venlafax-
ine in GAD (Narasimhan et al. 2011; Domschke and 
Deckert in press). Real et al. was also unable to reveal 
an association between rs6265 and success of treat-
ment with serotonin reuptake inhibitors in patients 
with OCD, however, in the same study a haplotype 
of five SNPs – including rs6265 – was found to be 
associated with treatment response (Real et al. 2009; 
Brandl et al. 2012; Fullana et al. 2012).
Possible effects of other polymorphisms of 
BDNF gene on treatment response in ADs were also 
investigated. In the above mentioned study by Real 
et al. rs1491850 was found to affect the outcome of 
antidepressant treatment in OCD (Real et al. 2009; 
Brandl et al. 2012). Preliminary results also suggest 
that C270T and rs2049045 SNP may influence treat-
ment response to S(S)RI therapy in OCD (Brandl et 
al. 2012). Domschke et al. found that the TT vari-
ant of another polymorphism in the BDNF gene 
(rs7124442) was associated with poorer treatment 
outcome among patients with anxious depression 
(Schosser and Kasper 2009; Tiwari et al. 2009; 
Domschke et al. 2010).
Catechol-O-methyltransferase (COMT)
The COMT enzyme is responsible for the inactiva-
tion of various catecholamines including dopamin, 
adrenalin and noradrenalin. It has been hypothesized 
that there is an interaction between the dopaminer-
gic and serotonergic systems in the development of 
depression and the response to antidepressive treat-
ment (Weizman et al. 2012). In addition, results of 
(imaging) genetic studies suggested that COMT is 
a possible player in the pathogenesis of ADs as well 
(Kolassa et al. 2010; Maron et al. 2010; Domschke 
and Deckert in press; Taylor in press).
Recently, Narasimhan et al. (2012) investigated 
the role of the rs4680 functional variant (also referred 
to as Val158Met) of the COMT gene in treatment 
response to venlafaxine in patients with GAD (Nar-
asimhan et al. 2012). After a six-month treatment 
period, they found that this polymorphism had no 
effect on treatment outcome if response was defined 
using the Hamilton Anxiety Scale. At the same time, 
if response was defined using the Clinical Global 
Impression of Improvement scale, an influence of 
this SNP was detectable on treatment outcome (al-
though the association did not withstand the Bonfer-
roni correction) (Narasimhan et al. 2012). The role of 
some other COMT gene polymorphisms (rs165737; 
rs165774; rs174696; rs174697 and rs165599) in treat-
ment response – which previously were found to be 
associated with treatment response in patients with 
MDD – were also studied in a GAD sample treated 
with duloxetine or placebo. According to the results, 
none of the examined COMT SNPs showed signifi-
cant associations with response to treatment with 
duloxetine in GAD patients, but two of them were 
associated with anxiety improvement in the placebo 
group (Perlis et al. in press).
Miguita et al. was not able to find an association 
between outcome of clomipramine treatment in 
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patients with OCD and Val158Met polymorphism 
of the COMT gene (Miguita et al. 2011; Brandl et al. 
2012). Results of Zhang et al. also did not support the 
role of variation of the COMT gene in OCD patients 
treated with serotonin reuptake inhibitors (Zhang 
et al. 2004). Notwithstanding, recently Vulink et al. 
demonstrated the effect of Val158Met SNP on citalo-
pram treatment response among patients with OCD 
(Vulink et al. 2012). Woo et al. found that the COMT 
Val158Met polymorphism is associated with treat-
ment response to paroxetine in patients with panic 
disorder (Woo et al. 2004; Andrisano et al. 2012).
Monoamine oxidase-A (MAO-A)
MAO-A is one of the enzymes that catalyzes the ex-
traneuronal breakdown of catecholamines (Weizman 
et al. 2012). Genetic variants of MAO-A are associ-
ated with susceptibility to some ADs (panic disorder, 
OCD, GAD and phobias) (Tadic et al. 2003; Samo-
chowiec et al. 2004; Maron et al. 2010; Domschke and 
Deckert in press; Taylor in press). At the same time, 
there is scarce data on the pharmacogenetic aspects 
of MAO-A in ADs: namely, Zhang et al. did not find 
an association between variants of MAO-A gene and 
treatment response to SRIs in OCD (Zhang et al. 2004; 
Brandl et al. 2012).
Dopamine receptors and the dopamine 
transporter (DAT)
Although their connection – based on sometimes 
ambiguous results of genetic, neuroimaging, pharma-
cological, etc. studies – with different kinds of ADs 
made them attractive targets, from the viewpoint of 
pharmacogenetics genes for dopamine receptors and 
DAT have been only scarcely studied in patients with 
ADs (Rowe et al. 1998; Tiwari et al. 2009; Durant et al. 
2010; Maron et al. 2010; Maron et al. 2010; Chang et 
al. 2012; Warwick et al. 2012; Taylor in press).
The Taq1 polymorphism of the DRD2 gene 
(a.k.a. rs1800497) was not associated with treat-
ments response to SRIs in OCD (Zhang et al. 2004; 
Narasimhan and Lohoff 2012). At the same time, 
Lawford et al. reported that subjects with PTSD 
carrying the DRD2 A1 allele were more likely to 
respond to treatment with paroxetine (Lawford et 
al. 2003). Recently, Perlis et al. found in a sample of 
patients with GAD that some variants of the DRD3 
gene (rs963468; rs167770; rs324023; rs324026) were 
associated with treatment response to duloxetine 
(Perlis et al. in press).
In the above-mentioned study by Zhang et al., authors 
also did not find associations between investigated 
DRD4 variations and success of SRI therapy (Zhang 
et al. 2004; Narasimhan and Lohoff 2012).
Miguita et al. investigated the effects of various 
DAT gene polymorphisms (i.e. the 40-bp VNTR in 
the 3’UTR; a 30-bpVNTR in intron 8; a VNTR in 
intron 14) on treatment response to clomipramine in 
patients with OCD, but they were unable to detect any 
significant associations (Miguita et al. 2011; Brandl 
et al. 2012).
Excitatory amino-acid transporter 3 (EAAT3)
Converging results of neuroimaging (MRS) and neu-
rochemical studies (measuring CSF glutamate levels) 
and also of animal models indicate that glutamatergic 
transmission is impaired in OCD (Wu et al. 2012; 
Real et al. in press). Furthermore, genetic studies 
reported that variants of the SLC1A1 gene encoding 
the glutamate transporter EAAC1/EAAT3 and also 
the GRIK2 gene encoding the kainate receptor subu-
nit 2 are probably associated with the risk of OCD 
(Wu et al. 2012; Real et al. in press; Taylor in press). 
According to the results of Real et al. who investigated 
seven SNPs in the SLC1A1 gene in a sample of 238 
OCD subjects, three SNPs (rs301434, rs301435 and 
rs3087879) were associated with treatment response 
(but only among those subjects free from stressful 
life events before onset of OCD) (Real et al. in press).
pharmaCogenetiC faCtors  
in the baCKground of anxiogeniC side 
effeCts of mediCations
Our knowledge concerning the genetic background of 
anxiety provides information not only with respect to 
therapeutic and adverse effects of anxiolytic medica-
tions and other medications used in the treatment of 
anxiety disorders, but can also be utilized to predict 
anxiogenic and depressogenic side effects of vari-
ous other medications and therefore help to identify 
those patients in whom application of these pharma-
cotherapies is likely to lead to such adverse effects. 
Rimonabant, an endocannabinoid 1 receptor (CB1) 
antagonist used as an appetite suppressant led to the 
emergence of depression and anxiety in about 20% 
of the patients taking it prompting the withdrawal of 
the medication from the market. This adverse effect 
of rimonabant is probably based on an interaction 
between CB1 receptors and the serotonergic system 
in the amygdala modulating depression and anxiety. 
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An interaction between the CB1 receptor gene (CNR1) 
and the serotonin transporter gene has been earlier 
reported in mediating anxiety, with a significantly 
higher trait anxiety in those carrying the ss variant 
of the 5-HTTLPR and the GG genotype of the CNR1 
rs2180619 polymorphism, due to a combined effect 
of a low expression of inhibitory CB1 receptors and 
low expression of the serotonin transporter respon-
sible for removing serotonin after release (Lazary et 
al. 2009). During stressful events, serotonin release 
increases in the amygdala activating postsynaptic 
5HT2C receptors, leading to increased anxiety (Bagdy 
et al. 2001) and through Gq activation (Turu et al. 
2009) increased synthesis of the endocannabinoid 
2-AG which acts as a retrograde neurotransmitter 
binding to presynaptic inhibitory CB1 receptors which 
in turn inhibit further release of serotonin (Lazary et 
al. 2011; Bagdy 2012). This negative feedback circuit 
shows higher activity in 5-HTTLPR ss carriers who 
manifest higher extracellular serotonin concentration 
due to a lower expression of the serotonin transporter, 
and is influenced by CB1 antagonists which may be 
one mechanism in the background of their anxiogenic 
effect (Lazary et al. 2009; Lazary et al. 2011; Kirilly et 
al. 2012; Kirilly et al. in press). Therefore investigating 
the CNR1 and 5-HTTLPR genotype may prove to be 
a useful tool in identifying those patients who would 
be at a risk of psychiatric side effects upon the use of 
CB1 antagonists.
results of therapygenetiC studies  
in anxiety disorders
The term therapygenetics was coined by Eley et al. 
to describe those lines of psychiatric genetic investi-
gations which aim at revealing the effect of specific 
genetic variants on success of psychotherapy. In the 
last few years a series of such investigations was con-
ducted (Eley et al. 2012).
Bryant et al. found in a preliminary study that ge-
netic variations affecting expression of SERT (namely 
the multimarker genotype which is the combination 
of 5-HTTLPR and rs25531) are associated with re-
sponse to cognitive behavior therapy (CBT) in pa-
tients with PTSD (Bryant et al. 2010). Authors found 
that PTSD subjects with low-expressing genotypes 
(s or Lg genotype carriers) had fewer treatment gains 
from CBT than patients with the high-expressing 
variant (La/La homozygotes) (Bryant et al. 2010). 
A recent study conducted by Eley et al. investigated 
whether treatment response of children receiving CBT 
for an AD is associated with the 5-HTTLPR genotype. 
Authors found that children with the ss genotype had 
better symptomatic response to CBT at follow-up 
compared to those carrying the sl or ll genotypes 
(Eley et al. 2012). A subsequent study was unable to 
confirm the results of Eley et al. on the association 
between 5-HTTLPR and response to CBT, however, 
this study was conducted in an adult population and 
participants suffered from depression and not from 
ADS (Bockting et al. in press).
A study by Lonsdorf et al. found that the func-
tional catechol-O-methyltransferase (COMT) Val-
158Met polymorphism had an effect on response to 
CBT in patients with panic disorder (response was 
diminished in met/met homozygotes as compared 
to patients carrying at least one val allele), while no 
influence of the SERT multimarker genotype (5-HT-
TLPR and rs25531) could be identified (Lonsdorf et 
al. 2010).
A study investigating the effect of the Val66Met 
(rs6265) SNP in the BDNF gene on response to CBT 
in patients with OCD found that met allele carriers 
had a lower response compared to patients not car-
rying the met allele (Fullana et al. 2012). At the same 
time, there was no effect of the rs6265 polymorphism 
of the BDNF gene on response to CBT in children 
with ADs; however, the same study demonstrated that 
presence of the T allele of the nerve growth factor 
(NGF) gene rs6330 polymorphism was associated 
with better treatment response (Lester et al. 2012).
At the same time, Hedman et al. found that none of 
the genetic variations including 5-HTTLPR, COMT 
Val158Met and BDNF Val66Met influenced the 
effectiveness of CBT in SAD (Hedman et al. 2012).
disCussion
As compared to the voluminous literature on pharma-
cogenetic results in affective disorders, to date there 
are only a relatively few papers on pharmacogenetics 
findings in ADs (Schosser and Kasper 2009; Dom-
schke and Deckert in press). Moreover, existing results 
so far are frequently controversial and unconfirmed. 
At the same time, since a large proportion of patients 
with different kinds of ADs do not sufficiently benefit 
from initial pharmacological and/or psychological 
treatment (i.e. their response- and full remission rates 
are considerably low), pharmacogenetic studies are 
needed to provide better prediction of treatment re-
sponse at the level of individuals (Van Ameringen et 
al. 2009; Diemer et al. 2010; Reinhold et al. 2011; Ipser 
and Stein 2012; Marazziti et al. 2012; Domschke and 
Deckert in press).
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Considering the three facts that 1) pharmacological 
treatment regimens for major depression and for ADS 
are quite similar; 2) these two groups of disorders 
are highly comorbid; and 3) there are a number of 
promising genetic candidates which have emerged 
from pharmacogenetic studies in major depression, 
we may suppose that in the near future those genetic 
variants which would be associated with treatment 
response in affective disorders will also be investigated 
in AD patients.
Results of these future studies may open up new 
avenues toward improved, more successful – and 
at the same time, personally tailored – treatment of 
anxiety disorders.
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A szorongásos betegségek a leggyakoribb mentális problémák közé tartoznak. Ezen kórképeket 
a korai betegségkezdet és gyakran a tünetek megjelenése és az adekvát kezelés kezdete között 
eltelt hosszú időszak jellemzi. A szorongásos betegségek genetikai meghatározottsága jól 
ismert, ugyanakkor a genetikai tényezők szerepe ezen zavarok gyógyszeres és pszichoterá-
piára adott válaszában kevéssé kutatott tudományterület. Bár számos vizsgálat foglalkozott 
a szerotonerg rendszer génjeinek szerepével, kevesebb tanulmány látott napvilágot olyan 
farmakokinetikai génvariánsokkal kapcsolatban, mint a citokróm P450 enzimrendszer, illetve 
a farmakodinámiás összefüggések szintjén a BDNF, COMT, MAO-A, a dopamine transzporter 
illetve a dopaminreceptorok, vagy az excitátoros aminosavtranszporter gén variánsai. Össze-
foglaló tanulmányunkban a szorongásos zavarok kezelésére adott terápiás válasz genetikai 
meghatározottságának szakirodalmát tekintjük át a szerotonerg rendszer génjein túlmenően, 
kitérve a pszichoterápiára adott válasz lehetséges genetikai meghatározóira is.
Kulcsszavak: szorongásos betegségek, farmakogenetika, terápiás válasz, szorongásoldók, 
benzodiazepinek, szelektív szerotonin visszavétel gátlók, pánikbetegség, PTSD
A szorongásos betegségek kezelésének farmakogenetikai  
aspektusai a szerotonerg rendszeren túl: rövid összefoglalás
